Abstract
Introduction
Peripheral artery disease (PAD) has increased in the general population due to people living longer and an epidemic of diabetes and obesity. Critical limb ischaemia (CLI) is the advanced stage of lower limb ischaemia (LLI), whose incidence in Western countries is estimated as being 220-1,000 new cases annually per million people [1] [2] [3] . CLI appears in 1-3% of newly diagnosed cases of LLI and in 5-10% of patients initially diagnosed with intermittent claudication during 5 years of observation [1] . CLI is linked to an approximately 25% annual risk of cardiovascular death, and a 30% probability of major amputation [1, 2] . In a recent study by Kay et al. [4] , among individuals with intermittent claudication, 1-and 3-year survival was respectively 98% and 96%, and in the CLI group, 1-and 3-year survival was respectively 74% and 51%. In a study by Soga et al. [5] , 41% of patients with CLI died over the course of 2 years, of which 47% died due to cardiovascular causes. In another summarization, a 5-year mortality rate of 70% was reported for patients with CLI, which meant that the number of deaths attributed to CLI was higher than the sum total of deaths due to coronary artery disease (CAD), breast cancer and colorectal cancer over the same period [6] . The large number of deaths among patients with CLI resulted, at least partially, from the perioperative mortality rate related to limb amputation, which ranges from 2.8% to 30% of hospital deaths, with 2.2% of deaths occurring within 30 days and 45% within 12 months [7] . These percentages would be more terrifying considering that in the US approximately 65-75 thousand major amputations (above and below the knee) are performed annually due to CLI [6] . The annual direct cost of CLI treatment in the US exceeds $25 billion. With obvious consequences of lower limb amputation one should also add the costs prosthetic, orthopaedic, rehabilitation and work absence.
The above-mentioned data show that CLI is a significant and resource-demanding problem. Intensive care is required for this clinical condition and consists of optimal medical treatment, physiotherapy, and endovascular and surgical treatment [1] [2] [3] [8] [9] [10] [11] . As the number of CLI patients treated percutaneously is increasing, it is important to be able to identify which patients are at greater risk of treatment failure, in order to allocate appropriately more intensive surveillance, aggressive or experimental treatment, or primary amputation for patients when the risk of treatment failure is high. Such CLI patient management might help avoid endangering patients and the unnecessary utilization of resources.
The aim of this study was to determine the factors affecting the risk of leg amputation among patients with CLI treated endovascularly as a first approach.
Material and methods
Between 1 January 2012 and 31 December 2014 in our clinic 39 major lower limb amputations of 37 limbs due to CLI were performed. CLI was defined as completing criteria of class IV-VI by Rutherford classification [1] . In 7 (18%) patients leg amputation was performed as a primary procedure (without previous endovascular treatment), and in 32 patients (82%) who were treated earlier endovascularly as a first approach due to CLI were retrospectively analysed. These 32 patients were further analysed as an investigated group. As a control group acted all consecutive 86 patients treated in our centre endovascularly due to CLI between 1 March 2011 and 31 December 2014, who had at least one ambulatory visit in 2015, but in whom leg amputation was not done. The date of the earliest endovascular procedure in group of patients with leg amputation was 1 March 2011. Demographic, clinical, biochemical and angiographic parameters of patients with leg amputation and with leg salvage were analysed and compared.
Measured outcomes
During the period between the performance of a percutaneous procedure and 31 August 2015, the target limb amputation (TLA) prevalence was measured. TLA was defined as the minor or major amputation of a previously stented limb during the follow-up period.
Bioethics
We were given permission to conduct the analysis by the local Bioethical Commission on 18 February 2014 (KB 139/2014) in accordance with an annex on 21 April 2015. The study was conducted in accordance with the Revised Declaration of Helsinki.
Statistics
Statistical analysis was performed using STATISTICA software for Windows 10.0 (StatSoft, Inc. 2011, STATISTICA, data analysis software system, version 10). The results are expressed as mean ± standard deviation. The following non-parametric tests were used to compare the values between the groups due to the inability to refute the hypothesis that the data were not normally distributed (Shapiro-Wilk test): the Mann-Whitney U test and Fisher's exact test. The Spearman's rank correlations were also checked. The variables determining the length of time between the first revascularization procedure and amputation were analysed using progressive stepwise regression. The association between the respective factors and TLA occurrence was verified using survival analysis, the Cox's F test, and the log-rank test as a part of the Kaplan-Meier method. Cox's proportional-hazards regression analysis models were created to identify predictors of clinical outcomes. The statistical significance level was set at a P-value of < 0.05.
Results
In our study, we analysed the data for 118 patients treated endovascularly as a first approach due to CLI.
In 32 (27%) of these patients, elective leg amputation due to unacceptable resting pain, necrosis and/or infection was undergone. The mean observation time between the first endovascular intervention and leg amputation in the 32 patients amounted to 220 ± 257 days (95% confidence interval [CI]: 122-319 days; median ± lower and upper quartile: 99 ± 42.5-295 days), and the mean observation time of the 86 patients in whom lower limb amputation was not performed amounted to 1310 ± 506 days (95% CI: 1,201-1,418.5 days; median ± lower and upper quartile: 1,198 ± 885-1,697 days) (Fig. 1) . In all patients only bare metal self-expanding stents were implanted (Tab. 1).
A comparison of demographic and clinical data at the date of the endovascular procedure between patients in whom lower limb amputation was performed and in individuals with a successful outcome to their endovascular procedure is presented in Table 1 . Patients with a leg amputation initially had the following: a higher class of Rutherford classification [1] ; were older, with a greater prevalence of comorbidities, such as: chronic cardiac failure, diabetes mellitus, and chronic kidney disease; had greater blood levels of glucose and creatinine; a greater international normalized ratio (INR); as well as a higher leukocyte and platelet count (Tab. 1). They also appeared to have more advanced target lesions according to the Trans-Atlantic Inter-Society Consensus (TASC) classification; the target lesion more frequently concerned arteries below the knee (BTK); and more frequently had at least two endovascular interventions performed (with at least one reintervention for target lesion revascularization [TLR]), defined as repeat percutaneous (endovascular) revascularization for a lesion anywhere within the stent or the 5 mm border proximal or distal to the stent due to symptom recurrence and target lesion occlusion (mainly due to in-stent restenosis, IRS) [12] . However, in patients with a leg amputation, percutaneous procedures were performed more frequently in those without stent implantation. Patients with a leg amputation also had a lower number of stents but the sum of their stent lengths was greater (Tab. 1).
In multivariate analysis (Tab. 2), the risk of leg amputation was significantly increased and amputation-free survival was shortened by (in order of hazard ratio [HR] value): history of dyslipidaemia, female gender, creatinine blood concentration (even in the normal range), history of TLR, smoking habit, Rutherford class, and leukocyte blood count. Whereas, the factors which decreased the risk of leg amputation were (in order starting with the lowest HR): statins use (decreased risk by 14 times), number of previous interventions, and LDL blood concentration (Tab. 2). It was interesting that age and advancement in angiographic severity of treated lesions classified according to TASC [1, 8] had no significant influence on the duration of the amputation-free period (Tab. 2). The short amputation-free survival shown for the least advanced lesions (TASC A) at the femoropopliteal vascular level (Fig. 2) should be recognized as bias, because this was related to the coexistence of more advanced lesions in the BTK region (the lack of the main calf vessels is more advanced than TASC D for infrapopliteal lesions [8] ). Diabetes mellitus, generally recognized as the strongest risk factor for lower limb amputation [1, 8, 9] , was significant only in the univariate Kaplan-Meier survival analysis (Fig. 3) .
Discussion
In our study, we tried to determine the risk factors for lower extremity amputation after endovascular intervention had been used as the first approach. Such management of CLI is widely accepted [1, 8, 13, 14] . We analysed the importance of demographic, clinical, biochemical, angiographic and periprocedural factors, in univariate, multivariate and survival analysis (Tab. 1, 2, Fig. 1-3) . We found that the strongest risk factor for leg amputation was history of dyslipidaemia (Tab. 2). In our study, the diagnosis of dyslipidaemia was based on medical history, in which the patient had reported previously elevated blood cholesterol and/or triglyceride concentration, independently of the current blood lipid level, and whether the patient had a history of hypolipidaemic drug use. In this sense, "dyslipidaemia" should be recognized as a long-acting factor, which begins its proatherogenic action in the patient's youth, and, according to the theory of cardiovascular continuum [15, 16] , has stimulated atherogenesis for many years, rendering insufficient the pharmacological control which had mostly been applied a few years before or on the day of the first endovascular procedure. Such an assumption explains why these patients had worse outcomes for endovascular interventions, probably related to multi-level lesions, including small vessels which are not suitable for any intervention. Such a suggestion is also supported by our data, which showed that the strongest factor reducing this risk of amputation was the use of statins, the most common and effective hypolipidaemic medicine (Tab. 2). Our observation corroborates reports by other authors who found that optimal medical treatment had a significant influence on the outcome of endovascular therapy [2, 3, 10, 11] , and statins helped to salvage limbs after percutaneous intervention [17] [18] [19] [20] [21] [22] [23] [24] [25] . Only Dosluoglu et al. [26] were unable to confirm a favourable statins effect on limb salvage. In the context of the above-mentioned data, the significant negative effect of blood LDL cholesterol level on the risk of amputation seems to be strange (Tab. 2). However, this effect was relatively weak (HR 0.97), which, in our opinion, supports the hypothesis that a low cholesterol level in patients with a leg amputation should be recognized, not as an atherosclerosis risk factor, but as a marker of the general severity of a patient's malnutrition status [27] . We also found a strong effect of female gender (HR of about 12), blood creatinine (HR of about 7), and smoking habit (HR of about 4) on the risk of leg amputation (Tab. 2). Worse outcomes for endovascular intervention and a greater risk of leg amputation among individuals with chronic kidney disease [1, 28] and in patients with an uncontrolled atherosclerosis risk factor [1-3, 8-10, 25] have previously been reported. However, in recent studies by Hedayati et al. [29] and Lo et al. [30] , women were more likely than men to have CLI (in our study, only 21% of the patients were female, Tab. 1), but they had a similar 12-month reintervention rate, and better amputation-free survival. Whereas, in the study by Vierthaler and the members of the Vascular Study Group of New England [7] , among other BTK -below-the-knee procedure; CAD -coronary artery disease; CHF -congestive heart failure; CI -confidence interval; INR -international normalized ratio for prothrombin time; LDL -low-density lipoprotein; MPV -mean platelet volume; TASC -Trans-Atlantic Inter-Society Consensus; TLR -target lesion revascularization However, according to the study by Selvarajah et al. [31] and widely accepted knowledge [1] [2] [3] 9] , active smokers had an increased risk of LLI progression and the failure of its treatment, pharmacologically, endovascularly and surgically. Our analysis showed the favourable effect of consecutive endovascular procedures on amputation delay, but also revealed that loss of primary stent patency (expressed by the need for TLR) or the absence of stent implantation led to worse outcomes (Tab. 1, 2). At the same time, we did not confirm an effect of angiographic lesion severity according to the TASC classification and our own runoff score for crus and foot on amputation-free survival (Tab. 2, Fig. 2) . However, such observations are consistent with other authors' reports, because the main factors affecting the outcome of endovascular interventions in patients with CLI were: severity of tissue loss, comorbidities and medication [3, 32] .
In our study, we also analysed the effect of cardiovascular medicines on limb salvage and amputation-free survival (Tab. 1, 2). However, we could only confirm the above-mentioned favourable effect of statins use. The importance of optimal medical treatment on patients with CLI is emphasized in another paper [3] . The favourable effect of cilostazol on patients with LLI following endovascular treatment has also been reported [33] .
Although our study showed statistically significant relationships between risk of leg amputation and a number of clinical factors, we could not avoid some methodological shortcomings that could have limited the strength of the deductions based on our results. First, our study was performed according to a retrospective study design with a relatively small group of patients. These factors make our multivariate analysis less reliable, and render it impossible to propose a risk stratification scale for further discussion and eventual validation.
Conclusions
The risk of major amputation following endovascular treatment in patients with CLI was associated with a number of patient characteristics, mainly: dyslipidaemia, gender, blood creatinine, smoking habit, medication, and the need for reintervention. For the purpose of limb salvage, patients with CLI need management of traditional atherosclerosis risk factors after endovascular treatment, as well as clinical and ultrasonographic surveillance in order to perform reinterventions with artery stenting which may extend amputation-free survival. As a result of the high risk of amputation in patients with CLI and the frequent need for re-intervention, large studies are needed to prepare a risk stratification scoring system for these patients, which, after further validation, could enable risk-adjusted patients to qualify for endovascular or surgical revascularization or for primary leg amputation. Such a scale could help to avoid endangering patients and the unnecessary utilization of resources.
